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On-demand pill protocol 
protects against HIV
Finally, there’s an effective prevention strategy—other 
than condoms—that can be used, as needed, by patients 
at high risk for HIV infection. 
PRACTICE CHANGER 
Offer patients at high risk for human immu-
nodeficiency virus (HIV), particularly men 
who have sex with men, preexposure prophy-
laxis (PrEP) with a combination pill of teno-
fovir disoproxil fumarate and emtricitabine 
(TDF-FTC) on an on-demand basis to de-
crease HIV-1 infection rates. 
STRENGTH OF RECOMMENDATION 
B: Based on one good quality randomized 
controlled trial.1
Molina JM, Capitant C, Spire B, et al. On-demand preexposure 
prophylaxis in men at high risk for HIV-1 infection.  N Engl J Med. 
2015;373:2237-2246. 
ILLUSTRATIVE CASE 
Your patient is a 31-year-old man who has sex 
with men. He is sexually active with several 
different partners. He asks you if there is any-
thing he can do to decrease his risk of becom-
ing infected with human immunodeficiency 
virus (HIV). Besides recommending condom 
use, what should you offer him?
In most high-income countries, including the United States, HIV-1 infection contin-ues to occur in high-risk groups, especially 
among men who have sex with men (MSM).2 
Without a vaccine, condom use has served as 
the primary method of preventing infection. 
In 2014, the Centers for Disease Control 
and Prevention (CDC) began recommending 
daily use of tenofovir disoproxil fumarate 
and emtricitabine (TDF-FTC) in high-risk 
individuals, as a form of preexposure 
prophylaxis (PrEP).3-5 This recommendation 
is based primarily on the Preexposure Pro-
phylaxis Initiative (iPrEx) trial, which showed 
a relative reduction of 44% (number needed 
to treat [NNT]=46 over 1.2 years) in the in-
cidence of new HIV-1 infection among men 
and transgender women who have sex with 
men when TDF-FTC was used on a daily ba-
sis.6 However, the effectiveness of this strat-
egy in the real world has not been as high as 
hoped, presumably because of the difficulty 
in getting patients to take the medication on 
a daily basis.7,8 
While it would likely improve adherence 
rates, the use of prophylaxis in an on-demand 
manner is not currently recommended.5 
That is because, until now, there have been 
no studies demonstrating the effectiveness 
of PrEP used episodically and taken only 
around the time of potential exposure. 
STUDY SUMMARY 
Fewer pills improves adherence,  
reduces HIV infection rates
The Intervention Preventive de l’Exposition 
aux Risques avec et pour les Gays (IPERGAY) 
study was a double-blind, multicenter study 
conducted in France and Canada that as-
sessed the efficacy and safety of prophylaxis 
with TDF-FTC used in an on-demand fash-
ion by MSM.1 The study hypothesis was that 
adherence would be higher if chemoprophy-
laxis was taken only around the time of inter-
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course, rather than daily, and that this would 
further reduce the risk of HIV infection. 
The study randomized 414 participants 
who were considered to be at high risk for 
acquiring HIV-1 infection. The investigators 
defined high risk as having a history of un-
protected anal sex with at least 2 partners 
in the previous 6 months. Other inclusion 
criteria included age ≥18 years, and male or 
transgender female sex. Exclusion criteria in-
cluded current HIV infection, hepatitis B or C 
infection, creatinine clearance <60 mL/min, 
alanine aminotransferase level >2.5 times the 
upper limit of normal, and significant glycos-
uria or proteinuria. 
❚ The pill and visit schedule. After ex-
cluding those who withdrew consent, were 
lost to follow-up, or who acquired HIV-1 infec-
tion, the study participants (199 in the TDF-
FTC group and 201 in the placebo group) were 
randomized to take TDF-FTC or placebo be-
fore and after sexual activity. The dose of TDF-
FTC was fixed at 300 mg of TDF and 200 mg of 
FTC per pill. The participants were instructed 
to take a loading dose of 2 pills of TDF-FTC or 
placebo with food 2 to 24 hours prior to inter-
course, followed by a third pill 24 hours after 
taking the first 2 pills, and a fourth pill 24 hours 
after the third pill. If there were multiple con-
secutive days with episodes of sexual inter-
course, participants were to take one pill on 
each of the days of intercourse, and then the 
2 post-exposure pills. If sexual activity re-
sumed within a week of the prior episode, par-
ticipants were instructed to take only one pill 
when resuming the preexposure prophylaxis; 
otherwise, they were to begin again with 2 pills 
2 to 24 hours prior to intercourse and repeat 
the protocol.
Study coordinators followed participants 
4 and 8 weeks after enrollment, and then 
every 8 weeks subsequently. The investiga-
tors tested the participants for HIV-1 and 
HIV-2 at each visit and assessed adherence by 
pill count and drug levels in plasma, as well 
as with an at-home, computer-assisted inter-
view completed by each participant prior to 
each visit. 
Participants received counseling from a 
peer community member and were offered 
preventative services and testing for other 
sexually transmitted infections. They were 
given free condoms and gel at each visit, as 
well as enough pills (TDF-FTC or placebo) to 
cover daily use until their next visit. 
❚ Forty-three percent took the pills 
correctly. The participants were followed for 
a median of 9.3 months. Overall, 72% of the 
participants took the study drugs (TDF-FTC 
or placebo), although 29% took a subopti-
mal dose. There was no change in the sexual 
behavior of the participants during the study. 
The study was unblinded after 20 months 
and is continuing as an open-label study 
because of the discontinuation of another 
preexposure prophylaxis study in the United 
Kingdom, which showed an NNT of 13 to 
prevent one new HIV infection per year.3 
An independent data and safety moni-
toring board recommended the unblinding 
because the placebo group was considered to 
be at significantly increased risk of contract-
ing HIV without PrEP. The open-label part of 
the study, iPrex-OLE, completed enrollment 
and data gathering in November 2013, and 
the data analysis and results are presently 
pending.9
 ❚ Eighty-six percent relative reduction 
in HIV. The primary end-point was the 
diagnosis of HIV-1 infection, and the results 
were based on an intention-to-treat analysis. 
HIV-1 infection was diagnosed in 19 study 
participants, with 3 of those new cases 
occurring between the time of randomiza-
tion and enrollment. Fourteen of the cases 
were in the placebo group (6.6 infections per 
100 person-years) and 2 of the new cases 
were in the TDF-FTC group (incidence 
0.91 per 100 person-years). This translated 
to a relative reduction in the incidence of new 
HIV-1 seroconversion in the TDF-FTC group 
of 86% (95% confidence interval, 40%-98%; 
P=.002; NNT=17 over 9.3 months). 
The 2 study participants in the TDF-
FTC group diagnosed with new HIV-1 were 
found to be non-adherent to the prescribed 
prophylaxis, as they returned 58 and 60 of 
the 60 pills administered to them, and no study 
drugs were found in their plasma samples. 
❚ Adverse events included gastrointes-
tinal symptoms of nausea, vomiting, diar-
rhea, and abdominal pain and were seen at a 
greater rate (14% vs 5%, P=.002; number 
needed to harm=11) in the treatment group 
We suspect  
the higher 
benefit of an 
on-demand PrEP 
is likely due 
to increased 
compliance with 
medication use.
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than in the placebo group. There were also 
mild increases in serum creatinine level 
(seen in 18% of the TDF-FTC group), but only 
2 participants had a transient decrease in cre-
atinine clearance to <60 mL/min. None of the 
participants discontinued medications due 
to renal issues. 
WHAT’S NEW 
Risk reduction with on-demand use  
is nearly double that of daily use
This is the first study to look at on-demand 
preexposure prophylaxis with TDF-FTC to 
decrease the incidence of HIV-1 infection 
in high-risk MSM. The risk reduction in this 
study (86%) was much better than the 44% 
seen in the prior study that used daily PrEP 
in this population.6 We suspect the higher 
benefit of on-demand PrEP is likely due to 
increased compliance with medication use.
CAVEATS 
Is fewer pills enough to maintain  
adherence over time?
The median length of follow-up in the study 
was 9.3 months. One concern is that adher-
ence may wane over time, decreasing the ef-
ficacy of the prophylaxis. Continued efforts 
to improve compliance with this type of PrEP 
may be needed to ensure efficacy. Since the 
study was shortened and reported early, we 
will need to wait for the results of the open-
label study to fully assess the risks of adverse 
events.
CHALLENGES TO IMPLEMENTATION 
Efficacy and convenience  
come at a cost
The main challenge to implementation could 
be the cost of TDF-FTC, the retail price of 
which is about $50 per dose.10 Insurance cov-
erage for the medication varies.                      JFP
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